We are pleased to announce the signing of an Exclusive License, Supply and Commercialization Agreement between Laboratorio Varifarma S.A. and CMC Pharma Solutions for the registration and commercialization of HIPULAR® Treprostinil across Latin America and Europe.
This agreement reinforces both companies’ commitment to the treatment of Pulmonary Arterial Hypertension (PAH).
Through the combination of HIPULAR® Treprostinil and the CRONO SC® ambulatory infusion pump from Canè S.p.A., CMC Pharma Solutions is bringing to patients and healthcare professionals a reliable therapeutic alternative that significantly contributes to improving the quality of life of people living with PAH.